Kathrine S Rallis1, Sam O Kleeman2, Michael Grant3, Katherine L Ordidge4, Anju Sahdev4, Thomas Powles3. 1. Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 2. Cold Spring Harbor Laboratory, New York, NY, USA; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: skleeman@cshl.edu. 3. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. 4. Imaging Department, St. Bartholomew's Hospital, London, UK.
Abstract
T-cell immunotherapy and molecular targeted therapies have become standard-of-care treatments for renal cell carcinoma (RCC). There is a need to develop robust biomarkers that predict patient outcomes to targeted therapies to personalise treatment. In recent years, quantitative analysis of imaging features, termed radiomics, has been used to extract tumour features. This narrative mini review summarises the evidence for radiomics prediction of immunotherapy and molecular targeted therapy outcomes in RCC. Radiomics may predict survival, treatment response, and disease progression in RCC treated with tyrosine kinase inhibitors (eg, sunitinib) and immune checkpoint inhibitors (eg, nivolumab). Further validation is necessary in large-scale studies. PATIENT SUMMARY: We summarise evidence on the ability of features extracted from CT (computed tomography) scans to predict patient outcomes from new treatments for kidney cancer. Although these features can predict treatment outcomes for patients, including survival, treatment response, and cancer progression, further research is necessary before this technology can be applied clinically.
T-cell immunotherapy and molecular targeted therapies have become standard-of-care treatments for renal cell carcinoma (RCC). There is a need to develop robust biomarkers that predict patient outcomes to targeted therapies to personalise treatment. In recent years, quantitative analysis of imaging features, termed radiomics, has been used to extract tumour features. This narrative mini review summarises the evidence for radiomics prediction of immunotherapy and molecular targeted therapy outcomes in RCC. Radiomics may predict survival, treatment response, and disease progression in RCC treated with tyrosine kinase inhibitors (eg, sunitinib) and immune checkpoint inhibitors (eg, nivolumab). Further validation is necessary in large-scale studies. PATIENT SUMMARY: We summarise evidence on the ability of features extracted from CT (computed tomography) scans to predict patient outcomes from new treatments for kidney cancer. Although these features can predict treatment outcomes for patients, including survival, treatment response, and cancer progression, further research is necessary before this technology can be applied clinically.
Authors: Lei Ye; Yuntian Chen; Hui Xu; Zhaoxiang Wang; Haixia Li; Jin Qi; Jing Wang; Jin Yao; Jiaming Liu; Bin Song Journal: Front Cell Dev Biol Date: 2022-02-25